DNA Methylation Detection Kit for Human SDC2, SEPTIN9 and TFPI2 Gene

Clinical Application Colorectal cancer (CRC) affects millions of people worldwide. It is unique in that it progresses slowly, making it preventable, and mortality can be significantly reduced through early detection. Testing using stool samples is more appropriate for screening efforts than colonoscopy because it is easier to conduct the program. Simultaneous testing with FIT not only greatly improves sensitivity and specificity, but is also more acceptable for widespread screening, or home sampling. DNA Methylation can be a novel marker of prognosis for tumor therapy, which is also a reversible process in which inactivated tumor suppressor genes are expressed through demethylation to exert a tumor suppressor effect. Therefore, demethylation can be used as a new direction in cancer treatment to monitor the dynamics of the disease.

Manual download

Details
Features
Specifications
Fit people

Details

Colorectal cancer CRC is a common malignant tumor in the gastrointestinal tract, as the name suggests, can occur in the colon and rectum, but the rectum and sigmoid colon are the most common, and the rest are found in the cecum, ascending colon, descending colon and transverse colon. Colorectal cancer is the third highest incidence of cancer in the country, and the incidence of colorectal cancer in urban populations has jumped to the second place, second only to lung cancer, with about 380,000 new cases and about 190,000 deaths every year. Most colorectal cancer progresses gradually from adenomas, and this process generally takes 5-10 years. Studies have shown that the 5-year survival rate of patients with stage 0~I bowel cancer surgery can be as high as 91.92%, while the 5-year survival rate of stage IV. patients is only 27.70% even if they have the opportunity to operate. Therefore, early diagnosis and early treatment can significantly improve the survival rate of colorectal cancer. Methylation is one of the genetic modification modalities and plays an important role in maintaining normal cell function, genetic imprinting, and embryonic development. Studies have found that abnormal gene methylation is closely related to the occurrence of cancer and can be used as molecular markers for early detection of cancer.

Features

Accurate: full intestinal detection, no detection blind zone, excellent detection performance
Early diagnosis: early detection of precancerous lesions and early bowel cancer;
Non-invasive: no bowel preparation required, only a stool sample;
Convenient: can be sampled at home and mailed at room temperature

The preferred product for early cancer screening, precision diagnosis and treatment, accurate quantification

Specifications

200 Tests/Kit

Fit people

Recommended screening population:
1. Population screening: public health people between 40-74 years old;
2. Waiting for screening: people with high-risk factors for colorectal cancer (family history of bowel cancer, history of intestinal surgery, chronic intestinal diseases, etc.), there is no age limit.

Products andSolutions

Professional and more focused